David Shook
Known title: Chief Medical OfficerCIK: 0001959742
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Nkarta Sets 2026 Data Reveal as CAR NK Trials Progress. Nkarta announced that it is targeting a data reveal for its outpatient CAR NK trials in 2026. The company said the trials are advancing, indicating progress toward a potential regulatory milestone. This development may influence how the market views the company’s future prospects. The stock is currently trading near its support level of $2.61.
Transaction History
| LYEL | ▼ Sell | Open Market | 500 | $6K | 9/10/2026 | View on chart |
| LYEL | ▼ Sell | Open Market | 1,977 | $25K | 6/10/2026 | View on chart |
| LYEL | ▲ Buy | Grant | 21,900 | $0 | 6/9/2025 | View on chart |
| NKTX | ▼ Sell | Open Market | 8,638 | $19K | 1/15/2025 | View on chart |
| NKTX | ▲ Buy | Grant | 59,000 | $0 | 1/3/2025 | View on chart |
| NKTX | ▲ Buy | Grant | 1,352 | $7K | 8/21/2024 | View on chart |
| NKTX | ▲ Buy | Grant | 23,421 | $0 | 7/15/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 456 | $3K | 6/18/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 3,552 | $31K | 1/16/2024 | View on chart |
| NKTX | ▲ Buy | Grant | 56,000 | $0 | 1/4/2024 | View on chart |
| NKTX | ▼ Sell | Open Market | 1,331 | $2K | 8/21/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 439 | $2K | 6/20/2023 | View on chart |
| NKTX | ▼ Sell | Open Market | 175 | $961 | 1/17/2023 | View on chart |
| NKTX | ▲ Buy | Grant | 37,500 | $0 | 1/13/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Lyell Immunopharma shares fall 27% over four weeks
The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.
Lyell Immunopharma shares fall 27% over four weeks. The stock has dropped about 27% in the past month, prompting a Yahoo article that discusses factors that could support a recovery. The piece notes the recent price weakness and points to potential catalysts that may improve sentiment. The decline leaves the share price near a key support level and the RSI is low, indicating oversold conditions.